{"id":1021088,"date":"2026-11-15T12:03:21","date_gmt":"2026-11-15T17:03:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/"},"modified":"2026-11-15T12:03:21","modified_gmt":"2026-11-15T17:03:21","slug":"helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/","title":{"rendered":"Helus Pharma to Present Topline Results from Phase 3 APPROACH Study\u00a0Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026"},"content":{"rendered":"<h2>\nCompany to host webcast at 8:00 a.m. EDT on Monday, November 16, 2026<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK and TORONTO, Nov.  15, 2026  (GLOBE NEWSWIRE) &#8212; Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the \u201cCompany\u201d or \u201cHelus Pharma\u201d), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development and commercialization of novel serotonergic agonists (\u201cNSAs\u201d), today announced that it will host a webcast tomorrow at 8:00 a.m. EDT to present topline results from its Phase 3 APPROACH study evaluating HLP003 in major depressive disorder (\u201cMDD\u201d).<\/p>\n<p align=\"justify\">Please <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JK-jsLmd1DOu_5n_hWOFvW7M0_WKnIfmtIzQ6WK656nRMTuFaCJjSTMbePRy_cZPOcSanqy1EFSRhNh09rNqsoXL5W6Rk2uqEtmFlT0eK7embB9-0UIkOrOAlJffBxHT\" rel=\"nofollow\" target=\"_blank\">click here<\/a> to access the webcast or visit the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XRjY6xUw7eKoAJsHFnRkfdsc1dCAYBOAjzw8Hgo9a9Apq6IXMPeQTVlRxI8qusO0y1tusdinebDVP3slc3vFWAB8BORtfzy-fQWYT5eSM0jBdOBdsushHF7dUirJ5bLG\" rel=\"nofollow\" target=\"_blank\">Events &amp; Presentations<\/a> page of Helus Pharma\u2019s website. The archived webcast will be available on the Company\u2019s website on the Events &amp; Presentations page following the presentation.<\/p>\n<p align=\"justify\">\n        <strong>About Helus Pharma<\/strong>\n      <\/p>\n<p align=\"justify\">Helus Pharma is a clinical stage pharmaceutical company committed to improving the treatment landscape in mental health through the development of NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company\u2019s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.<\/p>\n<p align=\"justify\">Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of MDD that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.<\/p>\n<p align=\"justify\">The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus Pharma\u2122 is a trademark of Helus Pharma Corp.<\/p>\n<p align=\"justify\">\n        <strong>Cautionary Notes and Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, \u201cforward-looking statements\u201d) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks, uncertainties, and other important factors which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as \u201cmay\u201d, \u201cshould\u201d, \u201ccould\u201d, \u201cpotential\u201d, \u201cpossible\u201d, \u201cintend\u201d, \u201cestimate\u201d, \u201cplan\u201d, \u201canticipate\u201d, \u201cexpect\u201d, \u201cbelieve\u201d or \u201ccontinue\u201d, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company\u2019s plans to present topline results from its Phase 3 APPROACH study on November 16, 2026; and plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions; and the timing of any of the foregoing.<\/p>\n<p align=\"justify\">These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; the results of the Company\u2019s clinical trials; the Company\u2019s ability to pursue and obtain regulatory approval for its product candidates; the Company\u2019s ability to enroll and retain participants in its clinical trials; the Company\u2019s need for additional financing; the Company\u2019s dependence on key personnel, including in connection with recent changes in management; the regulation of controlled substances; fluctuations in securities markets; expectations regarding the size of the NSA market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company&#8217;s operations; and the risk factors set out in each of the Company&#8217;s management&#8217;s discussion and analysis for the three and six months ended September 30, 2026, and the Company\u2019s annual information form for the year ended March 31, 2026, which are available under the Company&#8217;s profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov\/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.<\/p>\n<p align=\"justify\">The Company makes no medical, treatment or health benefit claims about the Company\u2019s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company\u2019s performance and operations.<\/p>\n<p align=\"justify\">\n        <em>Neither Cboe Canada, nor the Nasdaq Global Market stock exchange, have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Matthew Beck<br \/>astr partners<br \/>Managing Partner<br \/>(917) 415-1750<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RYNAPp8sAfKKORcLwo09AJoVqNgnQZhhdfw2uxgmpEpIcfIJOA57M57JMsIKHbplaVTateijtI3psdgL3lKtAGXC7HYokF7j2HW4KPzrs-wUoxpI1HqJNZWajvR_1Hwp\" rel=\"nofollow\" target=\"_blank\">Matthew.beck@astrpartners.com<\/a><\/p>\n<p align=\"justify\">Greg Cavers<br \/>Chief Financial Officer<br \/>Helus Pharma<br \/>1-866-292-4601 x715<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kK5tAAcvweHP0gfchjqWU89Apnl8sa_OZTKh8Sa-EkNGnADxejXgE8xgS6ZT5fgLkXI5vXdqBnQyTLmRK7WGzhPiqvXzlyNp_216yy5tHf8=\" rel=\"nofollow\" target=\"_blank\">irteam@helus.com<\/a> \u2013 or \u2013 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NyGWGRKmWunRt97cSvfnSJkdloVjkVg_wMsacWZz49BaPaE1DpghzwSQ16i4lkmqSWyW1_tQZ-mlr_SaMpU1_iAzjYnQ5T4UOsjb8jMJhnA=\" rel=\"nofollow\" target=\"_blank\">media@helus.com<\/a>\u00a0<\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Charlotte Wray<br \/>Chief Executive Officer<br \/>RXMD<br \/>(212) 537-9495<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=anNhVf6B5SwA3WAHRr4a3zUJCtm2pRBxvCleTM0Un9JfKexcaRUGTcNJVqeYuU3F72UWLyK9ZYHwlA78coma6fqkS8XKbMiDiUajRnl0OCE=\" rel=\"nofollow\" target=\"_blank\">cwray@rxmedyn.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NzkzMCM3OTY2NzY0IzIyMjIzNTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OWZhZjM0NGUtZWY1Yi00ZjA4LWExYWUtY2IxYzczMWNlNjg3LTEyMzM5MDMtMjAyNi0xMS0xNS1lbg==\/tiny\/Helus-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company to host webcast at 8:00 a.m. EDT on Monday, November 16, 2026 NEW YORK and TORONTO, Nov. 15, 2026 (GLOBE NEWSWIRE) &#8212; Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the \u201cCompany\u201d or \u201cHelus Pharma\u201d), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development and commercialization of novel serotonergic agonists (\u201cNSAs\u201d), today announced that it will host a webcast tomorrow at 8:00 a.m. EDT to present topline results from its Phase 3 APPROACH study evaluating HLP003 in major depressive disorder (\u201cMDD\u201d). Please click here to access the webcast or visit the Events &amp; Presentations page of Helus Pharma\u2019s website. The archived webcast will be available on the Company\u2019s website on the Events &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Helus Pharma to Present Topline Results from Phase 3 APPROACH Study\u00a0Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021088","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Helus Pharma to Present Topline Results from Phase 3 APPROACH Study\u00a0Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Helus Pharma to Present Topline Results from Phase 3 APPROACH Study\u00a0Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to host webcast at 8:00 a.m. EDT on Monday, November 16, 2026 NEW YORK and TORONTO, Nov. 15, 2026 (GLOBE NEWSWIRE) &#8212; Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the \u201cCompany\u201d or \u201cHelus Pharma\u201d), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development and commercialization of novel serotonergic agonists (\u201cNSAs\u201d), today announced that it will host a webcast tomorrow at 8:00 a.m. EDT to present topline results from its Phase 3 APPROACH study evaluating HLP003 in major depressive disorder (\u201cMDD\u201d). Please click here to access the webcast or visit the Events &amp; Presentations page of Helus Pharma\u2019s website. The archived webcast will be available on the Company\u2019s website on the Events &hellip; Continue reading &quot;Helus Pharma to Present Topline Results from Phase 3 APPROACH Study\u00a0Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-15T17:03:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NzkzMCM3OTY2NzY0IzIyMjIzNTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Helus Pharma to Present Topline Results from Phase 3 APPROACH Study\u00a0Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026\",\"datePublished\":\"2026-11-15T17:03:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\\\/\"},\"wordCount\":1026,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NzkzMCM3OTY2NzY0IzIyMjIzNTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\\\/\",\"name\":\"Helus Pharma to Present Topline Results from Phase 3 APPROACH Study\u00a0Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NzkzMCM3OTY2NzY0IzIyMjIzNTA=\",\"datePublished\":\"2026-11-15T17:03:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NzkzMCM3OTY2NzY0IzIyMjIzNTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NzkzMCM3OTY2NzY0IzIyMjIzNTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Helus Pharma to Present Topline Results from Phase 3 APPROACH Study\u00a0Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Helus Pharma to Present Topline Results from Phase 3 APPROACH Study\u00a0Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/","og_locale":"en_US","og_type":"article","og_title":"Helus Pharma to Present Topline Results from Phase 3 APPROACH Study\u00a0Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026 - Market Newsdesk","og_description":"Company to host webcast at 8:00 a.m. EDT on Monday, November 16, 2026 NEW YORK and TORONTO, Nov. 15, 2026 (GLOBE NEWSWIRE) &#8212; Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the \u201cCompany\u201d or \u201cHelus Pharma\u201d), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development and commercialization of novel serotonergic agonists (\u201cNSAs\u201d), today announced that it will host a webcast tomorrow at 8:00 a.m. EDT to present topline results from its Phase 3 APPROACH study evaluating HLP003 in major depressive disorder (\u201cMDD\u201d). Please click here to access the webcast or visit the Events &amp; Presentations page of Helus Pharma\u2019s website. The archived webcast will be available on the Company\u2019s website on the Events &hellip; Continue reading \"Helus Pharma to Present Topline Results from Phase 3 APPROACH Study\u00a0Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-15T17:03:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NzkzMCM3OTY2NzY0IzIyMjIzNTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Helus Pharma to Present Topline Results from Phase 3 APPROACH Study\u00a0Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026","datePublished":"2026-11-15T17:03:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/"},"wordCount":1026,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NzkzMCM3OTY2NzY0IzIyMjIzNTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/","name":"Helus Pharma to Present Topline Results from Phase 3 APPROACH Study\u00a0Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NzkzMCM3OTY2NzY0IzIyMjIzNTA=","datePublished":"2026-11-15T17:03:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NzkzMCM3OTY2NzY0IzIyMjIzNTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NzkzMCM3OTY2NzY0IzIyMjIzNTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helus-pharma-to-present-topline-results-from-phase-3-approach-study-evaluating-hlp003-as-adjunctive-treatment-in-major-depressive-disorder-on-november-16-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Helus Pharma to Present Topline Results from Phase 3 APPROACH Study\u00a0Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021088"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021088\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021088"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021088"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}